One-in-a-million people are living with EHE worldwide.

Our mission is to find treatments and a cure for this rare cancer by advancing research and driving collaboration between patients, researchers, and clinicians.

We envision a world where Epithelioid Hemangioendothelioma (EHE) is easily diagnosed and treatable. Join our dedicated community by subscribing to our emails.

Patient-Powered Research

Patients Powering Research for Epithelioid Hemangioendothelioma

EHE Global Patient Registry

The EHE Global Patient Registry empowers people with Epithelioid Hemangioendothelioma (EHE) to join together to improve our understanding of this ultra-rare sarcoma.

EHE Biobank

Patients are the key to finding new treatments for EHE! Researchers need tumor tissue, blood and fluid from EHE patients to understand disease progression and speed development of new drugs and therapies.

Patient Services

Whether you are newly diagnosed or have been living with EHE for a while, you are not alone. The EHE Community is stronger together and includes patients, their families and friends and the many specialists working tirelessly to find treatments and a cure. 

Latest EHE News, Events and Research

John McFadden joins The EHE Foundation Board of Directors.

Welcome New Board Member John McFadden, Ph.D., CRNA, APRN

By The EHE Foundation | November 17, 2023

The EHE Foundation was founded by patients, for patients. Continuing that tradition, we aredelighted to announce that EHE patient John McFadden, Ph.D., CRNA, APRN, has joined ourBoard of Directors. With more than 35 years of experience in health care, Dr. McFadden has held positions as anurse executive, hospital and university program accreditation surveyor, faculty member, […]

Read More
Together we give on Giving Tuesday

Giving Tuesday is November 28th

By The EHE Foundation | November 14, 2023

During the busy holiday season, The EHE Foundation asks that you join us in celebrating Giving Tuesday, not just on Tuesday, November 28th, but throughout the month of November. All proceeds will support our vision: a world where EHE is easily diagnosed and treatable. Retailers are bombarding us with Black Friday and Cyber Monday advertisements. Let […]

Read More
Nick Scalora and Munir Tanas

Spotlight on Young Investigator Nicholas Scalora, Advancing the Science Behind EHE

By The EHE Foundation | November 14, 2023

The EHE Foundation is proud to have awarded the 2023 Fellowship Travel Grant to Nicholas (Nick) Scalora, a 5th year graduate research assistant in the Tanas Laboratory, at the University of Iowa, where the team studies the role of the Hippo pathway in sarcomas. Dr. Munir Tanas, expert pathologist and researcher, was first author of […]

Read More
EHE at CTOS 2023

Highlights from CTOS 2023

By The EHE Foundation | November 8, 2023

Last week EHE Foundation Director of Research Denise Robinson, attended the Connective Tissue Oncology Society (CTOS) 2023 annual meeting in Dublin, Ireland. Every year, physicians, scientists, and advocates from around the world come together to advance patient care and increase knowledge in connective tissue tumors. EHE is one of over 100 subtypes of sarcoma, which […]

Read More
EHE Global Advocacy Meeting, Milan, Italy

EHE Global Research Convened in Milan, Italy

By The EHE Foundation | October 2, 2023

In September 2023, EHE Director of Research Denise Robinson met over three days in Milan, Italy, with patient advocates and researchers to discuss EHE research funded by this community. Exciting progress is happening in this multi-national collaborative research under the leadership of Dr. Silvia Stacchiotti and Dr. Nadia Zaffaroni (Istituto Nazionale Tumori IRCCS, Milan), and […]

Read More
The Lamar Lab

Funded Research Project Update: Use of pre-clinical EHE models to identify druggable pathways to treat EHE

By The EHE Foundation | September 7, 2023

Investigator: John Lamar, PhD, Albany Medical College Dr. Lamar was awarded a 3-year grant by The EHE Foundation in 2022, that aims to identify FDA-approved drugs that inhibit EHE cell growth, and then test them in pre-clinical mouse models for the treatment of EHE. What does this mean for patients? This could mean a shorter […]

Read More
The Pledge (Q4 2023)

The Pledge: Edition 35, Q4 – October-December, 2023

By The EHE Foundation | February 6, 2024

Publication of The Pledge quarterly newsletter is led by the EHE Rare Cancer Charity (UK). EHE patient advocacy groups from around the globe. provide content including research news, patient and fundraising stories, and much more! Click here to view the most recent edition of our online EHE newsletter, The Pledge.

Read More
Science Saturday: Patient-Powered Research

Science Saturday: Patient-Powered Research

By The EHE Foundation | January 31, 2024

Join The EHE Foundation’s Director of Research, Denise Robinson, as she explains the power of patients to advance research into EHE. What is patient-powered research, why does it matter, and how can you contribute? Join us to learn what’s happening in EHE research and the pivotal role you play in advancing our understanding of this […]

Read More
IK-930 Orphan Drug Designation

IK-930 Receives Orphan Drug Designation for EHE

By The EHE Foundation | January 10, 2024

Ikena Oncology has shared that on December 14th, 2023, the Food and Drug Administration (FDA) granted Orphan Drug Designation to IK-930 for the treatment of epithelioid hemangioendothelioma (EHE). We are excited about this designation following initial positive data from the IK-930 Phase I clinical trial published in Ikena’s November 9th press release. What does this […]

Read More